-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Su Xuejun, Chairman of Shijiazhuang Sihua Pharmaceutical Group, has been honored with the title of “2022 China Pharmaceutical Economy Person of the Year.”
Time：2023-02-21
On February 20, as the evening lights began to glow, the Zhuhai Hall of the Zhuhai Convention & Exhibition Center was filled with a vibrant atmosphere. Here, at the grand unveiling ceremony of one of the series of events for the 34th National Pharmaceutical Economic Information Conference—organized by the Southern Institute of Pharmaceutical Economics under the National Medical Products Administration and highly anticipated by the domestic pharmaceutical industry—the 2022 China Pharmaceutical Economic Person of the Year award was solemnly announced. Su Xuejun, Chairman of Shijiazhuang Fourth Pharmaceutical Group, was honored with the title of “2022 China Pharmaceutical Economic Person of the Year.”
On February 20, as the lights began to glow, the Zhuhai Hall at the Zhuhai Convention & Exhibition Center was filled with a vibrant atmosphere. Here, the highly anticipated 34th National Pharmaceutical Economic Information Conference—organized by the Southern Institute of Pharmaceutical Economics under the National Medical Products Administration—held one of its key events: the announcement of the 2022 China Pharmaceutical Economy Person of the Year award. Su Xuejun, Chairman of Shijiazhuang Sihua Pharmaceutical Group, was honored with the title of “2022 China Pharmaceutical Economy Person of the Year.”
In the award citation delivered by the conference organizing committee, it was noted that at a pivotal moment when the pharmaceutical industry is undergoing transformation and upgrading, moving toward high-quality development, Su Xuejun has led Shisi Pharmaceutical with an extraordinary spirit of “creativity,” “responsibility,” and “perseverance.” By focusing on genuine needs and championing original innovation, he has positioned the company as a powerhouse in pharmaceutical innovation, actively seizing strategic advantages in the development and innovation of the pharmaceutical industry. As a result, the company has unleashed unprecedented dynamism and demonstrated remarkable vision and ambition, emerging as a shining “star” benchmark that is currently leading the new mainstream of China’s pharmaceutical economy.
Faced with new changes in both domestic and international markets, in 2022, under the leadership of the Group’s Board of Directors, Shijiazhuang Four Pharmaceutical firmly focused on industry frontiers and market demands, accelerating the integration of its resource advantages—including raw materials, talent, technology, and capital—and strategically aligning innovation chains with industrial chains. The company rapidly advanced research and development in areas such as generic drugs, innovative drugs, specialty APIs, and products undergoing consistency evaluations. Its efficiency and output in developing specialty generic drugs consistently ranked among the top in China’s pharmaceutical enterprises, and its innovation capabilities have placed it among the top 50 Chinese companies in chemical drug R&D strength. Guided by innovation, the company has accelerated its move toward the high-end of the value chain, achieving a transformative upgrade from “single-industry dominance” to “multi-industry development.” At the same time, focusing on the “dual circulation” strategy, the company actively expanded into both domestic and overseas markets. Sales of finished dosage forms, APIs, and pharmaceutical packaging materials bucked the trend and posted strong growth, with key economic indicators reaching historic highs, enabling the company to leap forward and rise in the ranks of China’s top 100 pharmaceutical enterprises.
The “China Pharmaceutical Economy Person of the Year” is hailed as the “Oscar” of China’s pharmaceutical economy. Co-sponsored by the Southern Institute of Pharmaceutical Economics under the National Medical Products Administration and the Pharmaceutical Economy Newspaper, this award represents the most professional and influential recognition in China’s pharmaceutical industry. The recipients of the “China Pharmaceutical Economy Person of the Year” are carefully selected through a rigorous multi-stage process involving nomination and recommendation by the judging panel as well as expert evaluations. Each honoree serves as a quintessential exemplar of China’s current pharmaceutical economy and has made outstanding contributions to driving the transformation and upgrading of the pharmaceutical economy, leading innovation in industry products and markets, strategically managing capital, and promoting green production practices.
The east wind is mighty and sets the course for the future. This year’s selection uses the trajectory of pharmaceutical industry development as its coordinate system, defining the essence of the “Person of the Year” as “uniting the leading forces that are poised to embark on a new journey.” Candidates are evaluated against four key criteria—“responsibility, innovation, resilience, and influence”—with the aim of paying tribute to industry role models who strive relentlessly for responsibility and accountability, international recognition, steady diligence, and outstanding achievements, all in pursuit of the new-era vision of building a powerful pharmaceutical nation and strengthening the country through practical industrial endeavors, as well as to the backbone forces rising up on this new journey.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license